Research Use Only Notice: This article is intended only for qualified laboratory research personnel working in controlled institutional research settings. It discusses AOD9604 as a research-grade peptide for in-vitro cell-based assays and standardized laboratory animal model studies only. It does not provide instructions for human use, personal use, dosing, administration, reconstitution for non-laboratory purposes, veterinary treatment, cosmetic use, or any clinical application. No content in this article should be interpreted as promoting or enabling body composition management, personal experimentation, or any non-research application.
AOD9604, also described as Tyr-hGH177-191, is a synthetic peptide analog derived from the C-terminal region of human growth hormone. More precisely, it consists of the hGH amino-acid fragment 177-191 with an additional tyrosine residue at the N-terminus, producing a 16-amino-acid peptide commonly represented by the sequence YLRIVQCRSVEGSCGF.
The peptide contains an intramolecular disulfide bridge between Cys7 and Cys14 in the full Tyr-hGH177-191 sequence, corresponding to the Cys182-Cys189 disulfide region of full-length human growth hormone. This disulfide bond is an important element of the peptide’s molecular identity.[2][1]

From a molecular-identity perspective, AOD9604 should not be described merely as a generic “15-amino-acid hGH fragment.” The research molecule is more accurately identified as a 16-amino-acid N-terminal tyrosyl analog of hGH 177-191.
PubChem lists AOD9604 under CID 71300630 with the molecular formula C78H123N23O23S2, an average molecular weight of approximately 1,815.1 g/mol, a monoisotopic mass of approximately 1,813.8604 Da, and CAS Registry Number 221231-10-3.[2]
COA / MS interpretation note — average mass vs. monoisotopic mass: The 1,815.1 g/mol value corresponds to the average molecular weight, which is calculated using natural isotope abundance. MS-based COA documentation may report monoisotopic mass, average mass, neutral deconvoluted mass, charged ions, salt forms, adducts, or isotope envelopes depending on the analytical method and reporting convention.
Researchers comparing COA data against reference values should verify which mass convention, charge state, and adduct model the report uses before interpreting a measured value as a mass discrepancy.
Basic Research-Grade Molecular Parameters
| Parameter | Correct Research-Grade Description |
|---|---|
| Common Name | AOD9604 / AOD-9604 / Tyr-hGH177-191 |
| PubChem CID | 71300630 |
| Peptide Type | 16-amino-acid synthetic peptide analog of the hGH C-terminal fragment 177-191 |
| Sequence | YLRIVQCRSVEGSCGF |
| Structural Note | Intramolecular Cys7-Cys14 disulfide bridge; this corresponds to the Cys182-Cys189 disulfide region of full-length hGH, but the isolated short peptide is not structurally or functionally equivalent to the full-length protein. |
| Molecular Formula | C78H123N23O23S2 |
| Average Molecular Weight | Approximately 1,815.1 g/mol |
| Monoisotopic Mass | Approximately 1,813.8604 Da; relevant for MS-based COA interpretation when the method reports monoisotopic neutral mass. |
| CAS Number | 221231-10-3 |
| Typical Purity Statement | Lot-specific HPLC purity should be stated on the batch COA. Research-grade peptide lots are commonly specified by acceptance criteria such as ≥95%, ≥98%, or ≥99%, depending on intended research use and supplier specification. A universal purity claim should not be made without batch-specific analytical data. |
| Storage Statement | Lyophilized research material should be stored at −20°C or lower, dry, sealed, and protected from light unless the lot-specific COA or validated laboratory SOP states otherwise. |
| Solubility Statement | Solubility should be treated as batch-specific and assay-dependent. Solvent selection must be based on the lot-specific COA, the research assay matrix, and validated laboratory procedures. This article intentionally does not provide any non-laboratory preparation or use instructions. |
Molecular Design: Separating a C-Terminal hGH Fragment from Full-Length hGH Signaling
Full-length human growth hormone is a single-chain protein of 191 amino acids with two disulfide bonds, commonly described as Cys53-Cys165 and Cys182-Cys189. Its biological signaling profile is broader than that of a short C-terminal research peptide fragment and involves receptor-mediated signaling programs that are not equivalent to AOD9604 fragment studies.[3]
AOD9604 was designed as a stabilized analog of the C-terminal lipolytic-domain region of hGH residues 177-191. The additional N-terminal tyrosine differentiates it from the unmodified hGH 177-191 fragment and should be included when describing its molecular identity.
In research writing, this distinction is important because inaccurate wording such as “15-amino-acid AOD9604” or “unmodified hGH 177-191” can create a sequence-level error.
The Cys7-Cys14 disulfide bridge in AOD9604 corresponds to the Cys182-Cys189 disulfide region in full-length hGH. However, AOD9604 is an isolated short peptide rather than a folded 191-amino-acid protein.
Therefore, while the local disulfide relationship can be described accurately, the peptide’s conformational environment, receptor context, and biological interpretation should not be treated as equivalent to full-length hGH.
Growth hormone receptor biology is mediated through receptor-associated signaling pathways, including JAK-STAT signaling, whereas AOD9604 has been investigated as a fragment-based research tool with a narrower proposed relationship to adipocyte lipolysis models. The distinction between full-length hGH receptor signaling and fragment-associated experimental observations should be preserved throughout the article to avoid overstating mechanistic conclusions.[4]
Research Context: Adipocyte Lipolysis and Preclinical Model Studies
AOD9604 has been studied in preclinical metabolic research systems, including standardized laboratory rodent models and adipose-tissue-related experimental endpoints. Published work in Zucker rat models reported changes in adipose-tissue lipolytic activity after controlled experimental exposure to AOD9604.[5]
Such findings should be described only as laboratory animal model observations and must not be extrapolated to any human, consumer, cosmetic, veterinary, or personal-use setting.
Additional published research evaluated hGH and AOD9604 in laboratory mouse models, including beta(3)-adrenergic receptor knockout mice, and discussed the relationship between AOD9604-associated experimental observations and beta-adrenergic pathway biology. These findings support cautious discussion of AOD9604 as a research tool in adipocyte signaling studies, but they do not establish clinical efficacy, human safety, veterinary utility, or suitability for non-research use.[6]
In adipocyte biology, beta-adrenergic receptor signaling can activate cAMP-dependent pathways that regulate lipolytic enzymes such as hormone-sensitive lipase (HSL). Recent work on compartmentalized beta-adrenergic receptor/cAMP signaling has shown that beta1-AR, beta2-AR, and beta3-AR subtypes can activate distinct cAMP microdomains in white adipocytes, each differentially controlled by PDE3 and PDE4 phosphodiesterases.
These subtype- and compartment-specific pathways can produce different lipolytic responses even when overall cAMP amplitudes appear comparable. In insulin-resistant NZO mouse models, catecholamine-stimulated lipolysis has been reported to shift from beta1-AR toward beta3-AR dominance, with increased cAMP amplitude and lipolytic output and reduced PDE3 coupling.[7]
Mechanistic boundary note: The beta-adrenergic receptor/cAMP discussion above provides adipocyte-signaling background. It should not be interpreted as direct evidence that AOD9604 binds to, activates, or selectively modulates a specific beta-adrenergic receptor subtype.
Any connection between AOD9604 and beta-adrenergic pathway biology should remain model-specific and limited to the experimental systems in which it has been studied.
Therefore, when AOD9604 is discussed in relation to adipocyte lipolysis, the wording should remain model-specific and mechanistically cautious. The peptide has been investigated in research systems connected to adipocyte lipolytic signaling, but its precise molecular target and the degree to which its effects are direct or indirect remain research questions rather than settled universal conclusions.
Mechanistic Interpretation: What Can and Cannot Be Claimed
Acceptable wording for this article should use qualifying language such as “published preclinical studies suggest,” “in laboratory animal models,” “in adipocyte-related experimental systems,” and “under the tested experimental conditions.” Absolute statements such as “AOD9604 activates fat loss,” “AOD9604 safely produces metabolic benefits,” or “AOD9604 works without broader endocrine effects” should be avoided because they exceed the limits of the cited research evidence and may create regulatory and scientific risk.
A cautious mechanism statement is more appropriate: published preclinical research has investigated AOD9604 in relation to adipocyte lipolysis, beta-adrenergic pathway biology, and adipose-tissue metabolic endpoints, while the exact molecular interface through which the peptide influences these systems remains incompletely characterized.
This wording preserves the distinction between observed research endpoints and unproven broad biological claims.
For in-vitro adipocyte or adipocyte-like model systems, possible endpoints may include glycerol release, non-esterified fatty acid measurement, gene-expression readouts, lipid-droplet staining, or metabolic flux assays. The choice of beta-adrenergic subtype-specific controls, such as isoproterenol for non-selective beta-adrenergic activation or CL 316,243 for beta3-AR selective activation, should be guided by the species-specific adrenergic receptor profile of the model system.
However, any such endpoints must be described as laboratory assay measurements only. They should not be framed as evidence of human outcomes, clinical benefit, veterinary benefit, cosmetic benefit, or personal-use suitability.
Comparison with Related Laboratory Research Tools
| Research Tool / Agent | Research Context | Primary Experimental Use | Key Distinction from AOD9604 |
|---|---|---|---|
| AOD9604 | hGH C-terminal fragment analog; 16 amino acids; Cys7-Cys14 disulfide bridge; average MW approximately 1,815.1 Da. | Adipocyte lipolysis and lipid-metabolism pathway research in controlled laboratory systems. | Fragment-derived peptide with a proposed relationship to lipolytic signaling rather than full-length hGH receptor signaling. |
| Full-length hGH | Growth hormone receptor biology; 191 amino acids; two disulfide bonds, commonly described as Cys53-Cys165 and Cys182-Cys189. | Studies involving GHR-associated signaling pathways, including JAK-STAT biology. | Broader receptor-mediated signaling profile that should not be treated as equivalent to AOD9604 fragment research. |
| Isoproterenol | Beta-adrenergic receptor pharmacology. | Positive-control research tool for non-selective beta-adrenergic receptor-mediated lipolysis assays. | Non-selective beta-adrenergic agonist, not an hGH-derived peptide fragment. |
| CL 316,243 | Beta3-adrenergic receptor research. | Reference compound in beta3-AR-selective adipocyte biology studies, particularly in mouse models. | Direct beta3-adrenergic receptor agonist; mechanistically distinct from AOD9604. |
COA and Quality-Control Interpretation for Research Lots
For research-grade peptide lots, a COA should be interpreted as a laboratory raw-material quality document, not as evidence of safety, clinical utility, veterinary suitability, or suitability for any non-research application. A scientifically appropriate COA review should distinguish identity testing, purity testing, content determination, water content, residual solvents, and impurity profile rather than treating a single HPLC percentage as a complete quality assessment.
HPLC can support chromatographic purity assessment when the method is suitable for the intended purpose, while mass spectrometry can support molecular-identity confirmation by comparing observed mass data with the expected peptide mass. These tests answer different analytical questions and should not be conflated.
Researchers should note that HPLC purity and MS identity confirmation are complementary but distinct. Neither alone provides complete material characterization.
For AOD9604 specifically, the presence and preservation of the intended Cys7-Cys14 disulfide state should not be assumed from sequence data alone. Intact-mass LC-MS may support consistency with the oxidized peptide mass, but mass agreement alone may not fully establish disulfide connectivity, free-thiol status, or structural integrity under all analytical conditions.
Where disulfide integrity is important to assay interpretation, suitable methods may include non-reducing and reducing LC-MS comparison, MS/MS mapping, peptide mapping, free-thiol testing, or another qualified method appropriate to the laboratory context. Analytical procedures used for identity, purity, assay, and impurity evaluation should be fit for purpose and validated or qualified according to the laboratory context and applicable quality system.[8]
Impurity reporting should identify, where applicable, known process-related impurities, degradation products, specified and unspecified impurities, and total impurity levels. For chemically synthesized materials, ICH impurity guidance provides a general scientific framework for classifying, reporting, identifying, and qualifying impurities.
Because ICH Q3A(R2) expressly excludes peptide drug substances from its direct scope, it should be cited here only as a general impurity-control reference framework, not as a directly applicable peptide-specific compliance standard.
The exact application must be determined by the material type, regulatory context, and laboratory quality system.[9]
Residual solvent statements should not be vague. If residual solvents are relevant to a batch, they should be evaluated against a defined method and specification.
ICH Q3C provides a harmonized framework for residual-solvent classification and control; therefore, a COA should identify the tested solvent class or specific solvent panel when such testing is claimed.[10]
Laboratory Handling and Research-Only Limitations
Lyophilized AOD9604 research material should be handled as a controlled laboratory reagent. Storage conditions should be dry, sealed, protected from light, and generally maintained at −20°C or lower unless the lot-specific COA or validated institutional SOP provides a different instruction.
Once a peptide is prepared for an assay, solution stability should be established under the specific experimental conditions rather than assumed from general peptide identity alone.
The Cys7-Cys14 disulfide bridge is a potential stability-relevant structural element. Reducing conditions, inappropriate pH, oxidative stress, repeated freeze-thaw cycles, extended solution storage, or incompatible assay matrices may affect peptide integrity.
Researchers designing stability or long-duration assay protocols should include appropriate identity and disulfide-state monitoring where this structural element is relevant to assay interpretation.
This article intentionally does not provide reconstitution ratios, personal preparation steps, administration instructions, or any operational procedure that could be misapplied outside a professional laboratory. Any solvent selection, concentration calculation, or assay preparation must be performed only under qualified laboratory supervision, using the lot-specific COA, the assay protocol, and institutional safety procedures.
Appropriate Scientific Language for AOD9604 Articles
Scientifically appropriate AOD9604 content should remain limited to laboratory research contexts. Mechanistic statements should be tied to in-vitro systems, adipocyte-related assays, or standardized laboratory animal models.
The article should avoid words or phrases that imply human use, personal use, body-shaping use, cosmetic use, veterinary treatment, disease treatment, or clinical application.
Acceptable examples include:
- “Published preclinical studies investigated AOD9604 in adipose-tissue metabolic endpoints.”
- “In laboratory adipocyte-related experimental systems, AOD9604 has been discussed in relation to lipolytic signaling.”
- “Batch-specific identity and purity should be verified by appropriate analytical methods before quantitative research use, including suitable evaluation of the intended Cys7-Cys14 disulfide state where relevant to assay interpretation.”
- “The beta-adrenergic receptor/cAMP pathway may be discussed as adipocyte-signaling background, but it should not be presented as proof of a direct AOD9604 receptor target unless supported by specific experimental evidence.”
Non-compliant examples that should not appear in this article include any language suggesting personal use, self-directed preparation, human administration, veterinary treatment, clinical benefit, cosmetic benefit, disease intervention, or consumer-oriented outcomes.
Summary
AOD9604 is best described as a 16-amino-acid N-terminal tyrosyl analog of the hGH 177-191 C-terminal fragment, with the sequence YLRIVQCRSVEGSCGF, a Cys7-Cys14 disulfide bridge, molecular formula C78H123N23O23S2, average molecular weight of approximately 1,815.1 g/mol, monoisotopic mass of approximately 1,813.8604 Da, PubChem CID 71300630, and CAS Registry Number 221231-10-3. The Cys7-Cys14 disulfide relationship corresponds to the Cys182-Cys189 region of full-length hGH, but AOD9604 remains an isolated short peptide and should not be treated as structurally or biologically equivalent to the full-length hormone.
Its research relevance lies in adipocyte lipolysis and lipid-metabolism pathway studies, particularly in controlled in-vitro systems and standardized laboratory animal models. Claims about mechanism, potency, selectivity, quality, or experimental outcomes should remain qualified, model-specific, and supported by batch-specific analytical data and peer-reviewed research sources.
Background discussion of beta-adrenergic receptor/cAMP signaling may help frame adipocyte biology, but it should not be presented as direct evidence of AOD9604 receptor binding or direct beta-adrenergic receptor activation without specific supporting data.
The correct editorial framing is therefore narrow and research-only: AOD9604 may be discussed as a laboratory research peptide for studying adipocyte-related signaling and metabolic endpoints, but it must not be presented as a product for human use, veterinary use, cosmetic use, medical use, personal experimentation, or any non-research application.
Research Use Only Disclaimer
Research Use Only: The research-grade materials discussed in this article are intended exclusively for qualified laboratory research purposes and are not approved for human or veterinary use. This guide/article is provided for informational context regarding laboratory in-vitro/in-vivo research literature and experimental endpoints only, and does not constitute medical, clinical, veterinary guidance, treatment advice, or product-use instruction.